ISG15 Biomarker Detection for Proteinopathy Diagnosis
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods lack effective solutions for detecting and treating neurodegenerative diseases, which are chronic, incurable, and have unknown causes, placing a significant burden on patients and caregivers.
Innovation Solution
The development of compositions, methods, and kits for detecting and treating proteinopathies, specifically targeting the elevated ISG15 pathway, which is associated with impaired protein turnover and neurodegeneration in Ataxia Telangiectasia (A-T) and other neurodegenerative diseases.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If current diagnostic methods are used for neurodegenerative diseases, then diagnosis can be performed, but the causes remain unknown and effective treatment cannot be provided
Solution Approach 1:
The patent uses ISG15 protein levels as an intermediary biomarker to indirectly detect the underlying cause of neurodegeneration. By measuring ISG15, which is elevated in response to protein turnover impairment, the method provides information about the disease mechanism without directly observing the root cause, thus resolving the contradiction between diagnostic capability and cause identification.
2Ease of manufacture
If no specific therapeutic target is identified, then general care can be provided, but effective treatment for proteinopathy-induced neurodegeneration cannot be achieved
Solution Approach 1:
The patent identifies ISG15 pathway dysregulation as a specific therapeutic target and proposes modulating this pathway to treat proteinopathy-induced neurodegeneration. By changing the parameter of ISG15 pathway activity, the invention moves from general care to targeted therapy, improving treatment effectiveness while maintaining feasibility.
Data Source
AI summary
This invention is directed to compositions and methods for detecting and treating proteinopathies.